03.12.2012 - French researchers have identified how the body’s immune systems triggers therapy resistance to the cancer drugs gemcitabine and 5-fluorouracil.
The researchers, headed by François Ghiringhelli from INSERM in Dijon, found that in mice, the drugs activate a protein complex, termed Nlrp3 inflammasome, in myeloid derived suppressor cells. This activation leads to the release of the immune cell interleukin (IL)-1 beta, which then skews T immune cells to produce protumorigenic IL-17 and results in enhanced growth of tumours in mice (Nature Medicine, doi: 10.1038/nm.2999).
The chemotherapeutics were more efficacious at inhibiting tumour growth in mice lacking Nlrp3 or IL-17, or treated with an IL-1 receptor antagonist. The findings suggest that targeting the inflammasome pathway in conjunction with chemotherapy may improve its tumour killing efficacy by preventing the induction of protumorigenic immune responses.
25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.
21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.
11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.